Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)
about
Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy?Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directionsQuantitative Imaging Biomarkers of NAFLDGeneral review of magnetic resonance elastographyNonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment optionsNon-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatmentComparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis.Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease.Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A prospective study.Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective Study.Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin StudyMagnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysisComparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study.Non-invasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet?Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease.Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood.Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis.Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial.Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis.Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging.Caring for children with NAFLD and navigating their care into adulthood.Liver Fibrosis Quantification by Magnetic Resonance Imaging.MRI proton density fat fraction is robust across the biologically plausible range of triglyceride spectra in adults with nonalcoholic steatohepatitis.Optimization of region-of-interest sampling strategies for hepatic MRI proton density fat fraction quantification.MRI-determined liver proton density fat fraction, with MRS validation: Comparison of regions of interest sampling methods in patients with type 2 diabetes.Treatment options for nonalcoholic steatohepatitis - a safety evaluation.Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.Current and future treatment options in non-alcoholic steatohepatitis (NASH).Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview.Emerging and future therapies for nonalcoholic steatohepatitis in adults.Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice.Accuracy of PDFF estimation by magnitude-based and complex-based MRI in children with MR spectroscopy as a reference.Quantitation of the rates of hepatic and intestinal cholesterol synthesis in lysosomal acid lipase-deficient mice before and during treatment with ezetimibe.Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD).Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis.
P2860
Q26744631-F8157366-BCDE-40F9-A4A6-B619D153DDCAQ26751258-D215BD62-3788-4838-BC0D-FED47D0B8D60Q26768664-2397FF12-A1AD-442C-929E-B522A46E03A3Q26770398-7B19BF3F-D41B-4B08-ADB2-FF1126552284Q26796448-6589666D-F398-4370-BF03-DAF92126B784Q28080136-51162CC1-7FC9-41FA-B6C1-04EF1D0D4B10Q30248535-56BDA927-65E6-46DC-8663-871E557C14C5Q30355082-7DAB278E-7A3F-41F7-A4B3-B0802AF29F18Q30364476-130185A0-3C54-4738-8F63-ED7A9A7BC52EQ30366569-6284868A-2BDF-49AD-8A2E-887870542DF2Q30366572-1F1B77A6-C1C7-4C2F-82A3-A640ACCF9E29Q30368624-2041A31D-89CA-4DC3-B36A-17A1C955375AQ30372813-320B2ECC-7825-458D-9DBE-75CA5753CF8DQ30382172-AFDD7E4E-B4F8-4474-B601-DF627977E499Q30382278-995F710B-471F-4F2D-B488-05DAF743C8E7Q30389327-C1F52FE2-00BE-48E4-AE46-DD641A98EE80Q31134971-3D0585CC-B803-4D25-931B-55B51DF73C03Q34540703-473B9827-3515-4CF7-B7CC-2642970675F5Q36296929-4E6749BD-A303-4E11-B45B-6EC9EA66D88BQ36569181-7429419E-9C25-4C78-82B7-21E9DDF8FDB1Q36818351-62BB4B39-85B8-4897-ADF7-24F4D33CF13EQ37173770-670DE8F1-17FF-43FB-967C-208BB5B128F0Q37441985-FF09DD3B-A9E9-40EA-B914-E927E0F7D0CDQ38577570-B2A4EDFC-42C7-4E2F-BFC4-E75F5FF1CC61Q38600259-B7DF3E10-6C00-4D51-A9C6-98510C3344C2Q38603528-B6A8E6F8-5A69-496D-BDA8-BB47BEEE0657Q38607460-B4EF657D-FC2C-411F-A17C-E2C346CEBD67Q38625205-813AB4E3-ED5C-4A85-86AC-56D5F0830ED1Q38713765-9119297C-1FAB-4725-BC1F-D86FC877DF45Q38721038-5249B461-42F2-49C0-9894-E2C62C3088C7Q38748381-715780AE-5EF4-468C-96DD-DCF773329BB8Q38782562-A679030A-F67F-4B05-8539-8CE9A4F4D895Q38827586-95962649-1CA5-4BB2-BA27-EB787C681EF0Q38867031-0AE91CC5-C7E0-4F07-85FB-445A2E733A47Q38867829-74F540B6-D8D8-43AD-A524-1790C0E7FC3BQ38890679-0FB29755-6237-4D13-8195-2E5D2598D96DQ38891202-4C0A042C-4B2B-451B-8084-33C6C5359AE9Q38974667-07B83A31-7774-4ED4-BC82-77F343CB1BE1Q39170830-77048A5C-6E8F-4AAE-9B59-E551FCF1B1C6Q40154653-4C318E43-54ED-4FDC-AC79-0C60A43E82FE
P2860
Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Ezetimibe for the treatment of ...... andomized trial (MOZART trial)
@ast
Ezetimibe for the treatment of ...... andomized trial (MOZART trial)
@en
type
label
Ezetimibe for the treatment of ...... andomized trial (MOZART trial)
@ast
Ezetimibe for the treatment of ...... andomized trial (MOZART trial)
@en
prefLabel
Ezetimibe for the treatment of ...... andomized trial (MOZART trial)
@ast
Ezetimibe for the treatment of ...... andomized trial (MOZART trial)
@en
P2093
P2860
P50
P356
P1433
P1476
Ezetimibe for the treatment of ...... andomized trial (MOZART trial)
@en
P2093
Archana Bhatt
Brandon Ang
Catherine Hooker
Grace Y Lin
Joanie Salotti
Jonathan Hooker
Laura Hernandez
Linda Soaft
Lisa Richards
Mazen Noureddin
P2860
P304
P356
10.1002/HEP.27647
P407
P577
2015-02-27T00:00:00Z